Torrent Pharmaceuticals is currently trading at Rs. 1349.70, up by 41.85 points or 3.20% from its previous closing of Rs. 1307.85 on the BSE.
The scrip opened at Rs. 1340.40 and has touched a high and low of Rs. 1367.00 and Rs. 1340.40 respectively. So far 18546 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1367.00 on 18-Jun-2015 and a 52 week low of Rs. 655.50 on 14-Jul-2014.
Last one week high and low of the scrip stood at Rs. 1367.00 and Rs. 1245.20 respectively. The current market cap of the company is Rs. 22131.79 crore.
The promoters holding in the company stood at 71.25% while Institutions and Non-Institutions held 19.02% and 9.73% respectively.
Ahmedabad-based Torrent Pharma has received approval from Foreign Investment Promotion Board (FIPB) to raise the limit of investment by foreign institutional investors (FII) from 13.09 per cent to 35 per cent.
This would mean a total investment of about Rs 3,000 crore. This is the biggest approval announced by the Foreign Investment Promotion Board (FIPB) in value terms. Pharma and medical device approvals added up to Rs 4,000 crore of foreign investment.
Torrent had recently sealed a deal to acquire a 100 per cent stake in Zyg Pharma, a part of the Mumbai-based Encore Group, for an undisclosed sum. The deal is estimated to be valued at Rs 350-400 crore.
Torrent Pharmaceuticals is Flagship Company of the Torrent group, a leader in cardiovascular and central nervous system segments. It also has presence in gastro-intestinal, diabetology, anti-infective and pain management segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: